Akari Therapeutics (AKTX) Institutional Ownership $0.89 +0.13 (+16.90%) As of 11:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Akari Therapeutics (NASDAQ:AKTX)CurrentInstitutional OwnershipPercentage5.06%Number ofInstitutional Buyers(last 12 months)0Number ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$29.17K Get AKTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Akari Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data AKTX Institutional Buying and Selling by Quarter Akari Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails7/28/2025 Omnia Family Wealth LLC62,690$73K0.0%-28.5%0.195% 2/5/2024Omnia Family Wealth LLC87,628$273K0.1%+48.2%1.551% 11/15/2023Sabby Management LLC178,091$703K0.5%-97.6%3.152% 11/14/2022Armistice Capital LLC4,290,000$2.70M0.0%N/A5.762% 10/27/2022Omnia Family Wealth LLC782,372$493K0.4%+3.2%1.051% 5/6/2022Omnia Family Wealth LLC758,144$910K0.6%+13.7%1.277% 4/13/2022Hikari Power Ltd130,821$157K0.0%+45.7%0.220% 2/10/2022Wsfs Capital Management LLC100,000$150K0.1%N/A0.193% 2/4/2022Omnia Family Wealth LLC667,085$1.00M0.6%+42.8%1.285% 8/13/2021Renaissance Technologies LLC151,396$262K0.0%+14.0%0.318% 8/6/2021HighTower Advisors LLC26,000$45K0.0%N/A0.055% (Data available from 1/1/2016 forward) AKTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of AKTX shares? During the previous two years, the following institutional investors and hedge funds held shares of Akari Therapeutics shares: Sabby Management LLC ($703K), Omnia Family Wealth LLC ($73K).Learn more on Akari Therapeutics' institutional investors. What percentage of Akari Therapeutics' stock is owned by institutional investors? 5.06% of Akari Therapeutics' stock is owned by institutional investors. Learn more on AKTX's institutional investor holdings. Which institutional investors have been buying Akari Therapeutics' stock? The following institutional investors have purchased Akari Therapeutics' stock in the last 24 months: Omnia Family Wealth LLC ($28.51K). Which of Akari Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Akari Therapeutics stock in the last 24 months: Omnia Family Wealth LLC ($24.94K). How much institutional selling is happening at Akari Therapeutics? Institutional investors have sold a total of 24,938 shares in the last 24 months. This volume of shares sold represents approximately $29.17K in transactions. Related Companies Cassava Sciences Institutional Ownership Coya Therapeutics Institutional Ownership MacroGenics Institutional Ownership TScan Therapeutics Institutional Ownership Surrozen Institutional Ownership Oramed Pharmaceuticals Institutional Ownership Pliant Therapeutics Institutional Ownership Anebulo Pharmaceuticals Institutional Ownership ImmunoPrecise Antibodies Institutional Ownership Anixa Biosciences Institutional Ownership This page (NASDAQ:AKTX) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.